| Literature DB >> 32925936 |
Ewan P Plant1, Hasmik Manukyan1, Majid Laassri1, Zhiping Ye1.
Abstract
Understanding the extent and limitation of viral genome evolution can provide insight about potential drug and vaccine targets. Influenza B Viruses (IBVs) infect humans in a seasonal manner and causes significant morbidity and mortality. IBVs are negative-sense single-stranded RNA viruses with a segmented genome and can be divided into two antigenically distinct lineages. The two lineages have been circulating and further evolving for almost four decades. The immune response to IBV infection can lead to antibodies that target the strain causing the infection. Some antibodies are cross-reactive and are able to bind strains from both lineages but, because of antigenic drift and immunodominance, both lineages continue to evolve and challenge human health. Here we investigate changes in the genomes of an IBVs from each lineage after passage in tissue culture in the presence of human sera containing polyclonal antibodies directed toward antigenically and temporally distinct viruses. Our previous analysis of the fourth segment, which encodes the major surface protein HA, revealed a pattern of change in which signature sequences from one lineage mutated to the signature sequences of the other lineage. Here we analyze genes from the other genomic segments and observe that most of the quasispecies' heterogeneity occurs at the same loci in each lineage. The nature of the variants at these loci are investigated and possible reasons for this pattern are discussed. This work expands our understanding of the extent and limitations of genomic change in IBV.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32925936 PMCID: PMC7489522 DOI: 10.1371/journal.pone.0239015
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Names of viruses and sera.
| Serum | Year Serum Collected | HAI Titer toward Vaccine Antigen* | Victoria-Lineage Virus (passage number) | Yamagata-Lineage Virus (passage number) |
|---|---|---|---|---|
| none | N/A | N/A | B/CO/06/2017 (1) | B/Phuket/3073/2013 (1) |
| F09 | 2003 | 10 | COF09 (4) | PKF09 (4) |
| M50 | 2003 | 40 | COM50 (4) | PKM50 (3) |
| M74 | 2003 | 320 | COM74 (3) | PKM74 (3) |
| M09 | 2011 | 10 | COM09 (4) | PKM09 (4) |
| M56 | 2011 | 40 | COM56 (3) | PKM56 (4) |
| F16 | 2011 | 320 | COF16 (1) | PKF16 (3) |
The name of each serum used in the passage of virus, and the name of the resulting virus with passage number (in parentheses) is shown. N/A, not applicable; HAI, hemagglutination inhibition titer; * sera were collected from subjects that had received a trivalent vaccine containing a Victoria-lineage antigen in each of the two preceding seasons. Sera collected in 2003 was from subjects vaccinated with B/Hong Kong/330/2001, and sera collected in 2011 was from subjects vaccinated with B/Brisbane/60/2008. The vaccine viruses are antigenically and temporally distinct from the passaged viruses.
Fig 1
Fig 2Number of variant loci among segments.
The number of loci with variants present at levels greater than 5% in NGS data for ORFs in each segment are graphed. The loci are labelled as reciprocal or convergent as described in the text. Loci are further divided as either transitions (Ts) or transversions (Tv).
Fig 3Frequency of variants among ORFs and codons.
A; The percentage of nucleotides containing variants at levels greater than 5% is graphed for each ORF. B; The percentage of codons containing variants is graphed for each ORF. The percentage of codons with variants that result in nonsynonymous changes is graphed.
Comparison of dN/dS ratios.
| Segment | This study | Chen and Holmes, 2008 | Virk et al., 2020 (Victoria) | Virk et al., 2020 (Yamagata) |
|---|---|---|---|---|
| 0.10 | 0.04 | 0.004 | 0.018 | |
| 0.10 | 0.04 | 0.025 | 0.02 | |
| 0.08 | 0.07 | 0.034 | 0.035 | |
| 0.34 | 0.22 | 0.11 | 0.046 | |
| 0.15 | 0.07 | 0.05 | 0.038 | |
| 0.64 | 0.20 | 0.23 | 0.26 | |
| 0.06 | 0.03 | 0.04 | 0.005 | |
| 0.26 | 0.29 | 0.34 | 0.21 |
The ratio for non-synonymous to synonymous codon changes in the major ORF in each genomic segment was calculated using the variants identified in this study. Ratios from studies using sequence data from natural isolates are shown.